| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 67 | 2026 | 515 | 8.980 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2026 | 730 | 3.610 |
Why?
|
| Glaucoma | 16 | 2023 | 64 | 2.810 |
Why?
|
| Mutation | 42 | 2024 | 2661 | 2.790 |
Why?
|
| Glaucoma, Open-Angle | 14 | 2025 | 50 | 2.230 |
Why?
|
| Intraocular Pressure | 17 | 2025 | 73 | 1.680 |
Why?
|
| Profilins | 8 | 2024 | 44 | 1.500 |
Why?
|
| Genome-Wide Association Study | 20 | 2026 | 361 | 1.480 |
Why?
|
| Frontotemporal Dementia | 11 | 2024 | 157 | 1.440 |
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2026 | 509 | 1.350 |
Why?
|
| Exome | 10 | 2026 | 69 | 1.300 |
Why?
|
| Exfoliation Syndrome | 4 | 2025 | 9 | 1.190 |
Why?
|
| RNA-Binding Protein FUS | 7 | 2021 | 53 | 1.130 |
Why?
|
| Parkinson Disease | 2 | 2024 | 135 | 0.900 |
Why?
|
| Diabetic Retinopathy | 4 | 2019 | 60 | 0.900 |
Why?
|
| Humans | 115 | 2026 | 65140 | 0.880 |
Why?
|
| Motor Neurons | 11 | 2023 | 218 | 0.870 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2024 | 9 | 0.850 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2024 | 81 | 0.800 |
Why?
|
| Genetic Association Studies | 9 | 2018 | 120 | 0.800 |
Why?
|
| Lewy Body Disease | 1 | 2022 | 15 | 0.740 |
Why?
|
| Refraction, Ocular | 3 | 2012 | 8 | 0.710 |
Why?
|
| Refractive Errors | 3 | 2010 | 13 | 0.690 |
Why?
|
| Aged | 41 | 2025 | 14965 | 0.680 |
Why?
|
| Aged, 80 and over | 25 | 2025 | 5614 | 0.660 |
Why?
|
| Male | 58 | 2025 | 31047 | 0.640 |
Why?
|
| Visual Fields | 6 | 2025 | 51 | 0.640 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2010 | 8 | 0.630 |
Why?
|
| Ocular Hypertension | 3 | 2023 | 10 | 0.620 |
Why?
|
| DNA Repeat Expansion | 5 | 2024 | 58 | 0.620 |
Why?
|
| Middle Aged | 41 | 2025 | 18273 | 0.610 |
Why?
|
| Female | 58 | 2025 | 34018 | 0.610 |
Why?
|
| Rural Population | 5 | 2012 | 223 | 0.610 |
Why?
|
| Aryldialkylphosphatase | 2 | 2010 | 19 | 0.600 |
Why?
|
| C9orf72 Protein | 10 | 2024 | 114 | 0.590 |
Why?
|
| Cohort Studies | 17 | 2021 | 2620 | 0.590 |
Why?
|
| Case-Control Studies | 15 | 2025 | 1141 | 0.590 |
Why?
|
| Loss of Function Mutation | 2 | 2021 | 24 | 0.590 |
Why?
|
| Cataract Extraction | 3 | 2022 | 36 | 0.570 |
Why?
|
| Visual Acuity | 6 | 2020 | 134 | 0.550 |
Why?
|
| Australia | 12 | 2023 | 130 | 0.550 |
Why?
|
| NIMA-Related Kinase 1 | 2 | 2023 | 4 | 0.540 |
Why?
|
| Tubulin | 2 | 2015 | 73 | 0.530 |
Why?
|
| Neurons | 9 | 2021 | 933 | 0.530 |
Why?
|
| Cataract | 2 | 2020 | 54 | 0.520 |
Why?
|
| Genetic Testing | 6 | 2025 | 141 | 0.520 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2024 | 160 | 0.490 |
Why?
|
| Cornea | 2 | 2020 | 35 | 0.470 |
Why?
|
| Cytoskeletal Proteins | 6 | 2020 | 204 | 0.460 |
Why?
|
| Phacoemulsification | 2 | 2020 | 8 | 0.460 |
Why?
|
| Pedigree | 8 | 2024 | 193 | 0.460 |
Why?
|
| Retinal Ganglion Cells | 3 | 2020 | 30 | 0.450 |
Why?
|
| Vision Disorders | 2 | 2012 | 69 | 0.450 |
Why?
|
| Phenotype | 8 | 2022 | 1233 | 0.450 |
Why?
|
| Young Adult | 16 | 2021 | 4809 | 0.450 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2014 | 2 | 0.430 |
Why?
|
| Amino Acid Sequence | 7 | 2021 | 1589 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 6 | 2016 | 414 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2017 | 11 | 0.420 |
Why?
|
| Tonometry, Ocular | 6 | 2025 | 20 | 0.410 |
Why?
|
| Lenses, Intraocular | 2 | 2010 | 7 | 0.410 |
Why?
|
| Proteins | 6 | 2023 | 764 | 0.400 |
Why?
|
| Adult | 28 | 2025 | 17358 | 0.400 |
Why?
|
| Northern Territory | 5 | 2019 | 6 | 0.400 |
Why?
|
| Trabeculectomy | 2 | 2020 | 9 | 0.400 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 180 | 0.390 |
Why?
|
| Tomography, Optical Coherence | 3 | 2020 | 235 | 0.390 |
Why?
|
| Trachoma | 1 | 2012 | 3 | 0.380 |
Why?
|
| Genotype | 12 | 2019 | 673 | 0.380 |
Why?
|
| Haplotypes | 4 | 2012 | 134 | 0.370 |
Why?
|
| Neurodegenerative Diseases | 3 | 2024 | 152 | 0.370 |
Why?
|
| Vision, Low | 1 | 2012 | 11 | 0.360 |
Why?
|
| Mutant Proteins | 1 | 2012 | 105 | 0.360 |
Why?
|
| Blindness | 1 | 2012 | 43 | 0.360 |
Why?
|
| Actins | 4 | 2019 | 264 | 0.350 |
Why?
|
| Risk Factors | 15 | 2025 | 5429 | 0.340 |
Why?
|
| Optic Disk | 5 | 2025 | 26 | 0.340 |
Why?
|
| Membrane Proteins | 5 | 2019 | 919 | 0.340 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2019 | 103 | 0.330 |
Why?
|
| Esterases | 1 | 2010 | 13 | 0.320 |
Why?
|
| Drosophila | 6 | 2021 | 480 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 687 | 0.320 |
Why?
|
| Visual Field Tests | 1 | 2010 | 24 | 0.320 |
Why?
|
| Eye | 1 | 2010 | 59 | 0.320 |
Why?
|
| Functional Laterality | 1 | 2010 | 140 | 0.310 |
Why?
|
| Multifactorial Inheritance | 3 | 2025 | 26 | 0.310 |
Why?
|
| Incidence | 6 | 2017 | 1419 | 0.310 |
Why?
|
| Axonal Transport | 2 | 2022 | 32 | 0.310 |
Why?
|
| Interferometry | 1 | 2009 | 4 | 0.300 |
Why?
|
| Biometry | 1 | 2009 | 13 | 0.300 |
Why?
|
| Genetic Variation | 4 | 2026 | 394 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 440 | 0.290 |
Why?
|
| Active Transport, Cell Nucleus | 4 | 2023 | 115 | 0.290 |
Why?
|
| DNA Copy Number Variations | 3 | 2017 | 72 | 0.280 |
Why?
|
| Low Tension Glaucoma | 2 | 2017 | 5 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 333 | 0.260 |
Why?
|
| Ultrasonography | 1 | 2009 | 489 | 0.250 |
Why?
|
| Axons | 3 | 2020 | 124 | 0.250 |
Why?
|
| SMN Complex Proteins | 2 | 2021 | 6 | 0.250 |
Why?
|
| Animals | 21 | 2021 | 21345 | 0.250 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2025 | 13 | 0.250 |
Why?
|
| Eye Proteins | 3 | 2020 | 73 | 0.240 |
Why?
|
| Genetic Counseling | 1 | 2025 | 16 | 0.230 |
Why?
|
| Mutation, Missense | 4 | 2024 | 190 | 0.230 |
Why?
|
| Proteomics | 2 | 2025 | 293 | 0.230 |
Why?
|
| DNA-Binding Proteins | 6 | 2020 | 1225 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2017 | 12 | 0.220 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 100 | 0.220 |
Why?
|
| Drug Repositioning | 1 | 2024 | 11 | 0.220 |
Why?
|
| Microfilament Proteins | 3 | 2019 | 115 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 4 | 2015 | 428 | 0.210 |
Why?
|
| Proteome | 1 | 2025 | 152 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2483 | 0.210 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 25 | 0.210 |
Why?
|
| Superoxide Dismutase | 3 | 2022 | 222 | 0.210 |
Why?
|
| Disease Progression | 8 | 2021 | 1220 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 2701 | 0.200 |
Why?
|
| Prospective Studies | 8 | 2023 | 3308 | 0.190 |
Why?
|
| Mice | 12 | 2020 | 11119 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2025 | 6872 | 0.190 |
Why?
|
| Exons | 4 | 2019 | 208 | 0.190 |
Why?
|
| Ataxin-2 | 1 | 2022 | 4 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 2293 | 0.190 |
Why?
|
| Nerve Fibers | 2 | 2020 | 31 | 0.190 |
Why?
|
| Golgi Apparatus | 2 | 2019 | 65 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 15 | 0.180 |
Why?
|
| Lens, Crystalline | 1 | 2022 | 16 | 0.180 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2021 | 17 | 0.180 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2021 | 21 | 0.170 |
Why?
|
| Penetrance | 2 | 2020 | 11 | 0.170 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 27 | 0.170 |
Why?
|
| Transcription Factors | 3 | 2018 | 1556 | 0.170 |
Why?
|
| Quantitative Trait Loci | 3 | 2021 | 81 | 0.170 |
Why?
|
| Neuroprotective Agents | 2 | 2024 | 78 | 0.170 |
Why?
|
| Gene Expression | 3 | 2019 | 852 | 0.170 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2021 | 12 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2011 | 252 | 0.170 |
Why?
|
| Age Distribution | 2 | 2011 | 262 | 0.160 |
Why?
|
| Superoxide Dismutase-1 | 5 | 2023 | 148 | 0.160 |
Why?
|
| Macular Degeneration | 1 | 2023 | 195 | 0.160 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 50 | 0.160 |
Why?
|
| Thiazoles | 2 | 2019 | 45 | 0.160 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2020 | 5 | 0.160 |
Why?
|
| Alleles | 4 | 2021 | 453 | 0.160 |
Why?
|
| Neuropathology | 1 | 2019 | 3 | 0.160 |
Why?
|
| Heterozygote | 4 | 2022 | 173 | 0.160 |
Why?
|
| Huntingtin Protein | 1 | 2020 | 147 | 0.150 |
Why?
|
| Netherlands | 2 | 2016 | 26 | 0.150 |
Why?
|
| DNA Methylation | 2 | 2022 | 302 | 0.150 |
Why?
|
| Antigens, Ly | 1 | 2019 | 44 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2018 | 94 | 0.150 |
Why?
|
| Nuclear Pore | 1 | 2019 | 23 | 0.150 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 48 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 87 | 0.150 |
Why?
|
| Glycosyltransferases | 1 | 2019 | 9 | 0.150 |
Why?
|
| Histone Acetyltransferases | 2 | 2010 | 59 | 0.150 |
Why?
|
| Whole Genome Sequencing | 4 | 2021 | 85 | 0.150 |
Why?
|
| Receptors, AMPA | 1 | 2019 | 42 | 0.150 |
Why?
|
| Macula Lutea | 1 | 2019 | 26 | 0.150 |
Why?
|
| Homeostasis | 2 | 2023 | 379 | 0.140 |
Why?
|
| Equipment Design | 2 | 2010 | 363 | 0.140 |
Why?
|
| Age of Onset | 3 | 2017 | 174 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 1559 | 0.140 |
Why?
|
| Cell Line | 6 | 2019 | 2024 | 0.140 |
Why?
|
| Glutamic Acid | 1 | 2019 | 103 | 0.140 |
Why?
|
| Vitrectomy | 1 | 2019 | 34 | 0.140 |
Why?
|
| Medical Audit | 1 | 2019 | 67 | 0.140 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 21 | 0.140 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 177 | 0.140 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Wallerian Degeneration | 1 | 2018 | 8 | 0.140 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 242 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 198 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2019 | 200 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 105 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2016 | 364 | 0.130 |
Why?
|
| Annexins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 663 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2019 | 210 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2019 | 275 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 40 | 0.120 |
Why?
|
| CpG Islands | 1 | 2017 | 219 | 0.120 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 83 | 0.120 |
Why?
|
| Sirtuin 2 | 1 | 2016 | 6 | 0.120 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 333 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2016 | 12 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 132 | 0.120 |
Why?
|
| Myelin Proteins | 1 | 2016 | 30 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 149 | 0.120 |
Why?
|
| Skin | 2 | 2019 | 422 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2019 | 1574 | 0.120 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 62 | 0.120 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 33 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 555 | 0.120 |
Why?
|
| Cyclins | 1 | 2016 | 41 | 0.120 |
Why?
|
| Hand Dermatoses | 1 | 2016 | 4 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2021 | 616 | 0.120 |
Why?
|
| Sweet Syndrome | 1 | 2016 | 7 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 790 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2021 | 2061 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1630 | 0.120 |
Why?
|
| South Australia | 2 | 2019 | 4 | 0.120 |
Why?
|
| Calcium | 1 | 2019 | 584 | 0.120 |
Why?
|
| Adolescent | 6 | 2021 | 6297 | 0.120 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2015 | 3 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 794 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 447 | 0.110 |
Why?
|
| Prevalence | 3 | 2018 | 1445 | 0.110 |
Why?
|
| Scotoma | 1 | 2015 | 6 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 277 | 0.110 |
Why?
|
| Drosophila Proteins | 2 | 2019 | 758 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2019 | 630 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 171 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 59 | 0.110 |
Why?
|
| Glycoproteins | 2 | 2020 | 189 | 0.110 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2015 | 15 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 4 | 2018 | 78 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 312 | 0.110 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hydro-Lyases | 1 | 2014 | 9 | 0.110 |
Why?
|
| Hyperopia | 1 | 2014 | 1 | 0.110 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2014 | 1 | 0.110 |
Why?
|
| Microphthalmos | 1 | 2014 | 3 | 0.110 |
Why?
|
| Huntington Disease | 1 | 2016 | 160 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 24 | 0.110 |
Why?
|
| Animals, Genetically Modified | 3 | 2021 | 312 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2016 | 321 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2017 | 506 | 0.100 |
Why?
|
| Brain | 3 | 2021 | 1605 | 0.100 |
Why?
|
| Clinical Laboratory Services | 1 | 2014 | 5 | 0.100 |
Why?
|
| Protein Conformation | 2 | 2015 | 792 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2019 | 918 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2019 | 713 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 1698 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 1979 | 0.090 |
Why?
|
| Dependovirus | 1 | 2019 | 751 | 0.090 |
Why?
|
| Gene Frequency | 4 | 2014 | 122 | 0.090 |
Why?
|
| Jews | 1 | 2012 | 10 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2012 | 33 | 0.090 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 47 | 0.090 |
Why?
|
| Fluorescein Angiography | 1 | 2013 | 63 | 0.090 |
Why?
|
| Growth Cones | 1 | 2012 | 14 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 295 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 23 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 863 | 0.090 |
Why?
|
| Founder Effect | 1 | 2012 | 10 | 0.090 |
Why?
|
| Introns | 1 | 2013 | 114 | 0.090 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 3 | 0.090 |
Why?
|
| Autophagy | 1 | 2015 | 237 | 0.090 |
Why?
|
| Transcription Factor TFIIIA | 3 | 2018 | 7 | 0.090 |
Why?
|
| Point Mutation | 1 | 2012 | 168 | 0.090 |
Why?
|
| DNA | 1 | 2017 | 858 | 0.090 |
Why?
|
| Ubiquitination | 1 | 2012 | 117 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 113 | 0.090 |
Why?
|
| Neurogenesis | 1 | 2012 | 64 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2188 | 0.090 |
Why?
|
| Distal Myopathies | 1 | 2011 | 6 | 0.090 |
Why?
|
| Contractile Proteins | 1 | 2011 | 14 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2011 | 208 | 0.090 |
Why?
|
| Health Services Research | 1 | 2012 | 265 | 0.080 |
Why?
|
| Membrane Transport Proteins | 3 | 2018 | 135 | 0.080 |
Why?
|
| Protein Domains | 2 | 2024 | 154 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 219 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 226 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 1163 | 0.080 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2010 | 11 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 2102 | 0.080 |
Why?
|
| Child | 3 | 2021 | 4607 | 0.080 |
Why?
|
| Cholesterol | 2 | 2022 | 261 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 513 | 0.080 |
Why?
|
| Health Surveys | 1 | 2011 | 316 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 179 | 0.080 |
Why?
|
| Potassium Channels | 1 | 2010 | 55 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 130 | 0.080 |
Why?
|
| Multifunctional Enzymes | 1 | 2010 | 19 | 0.080 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2010 | 11 | 0.080 |
Why?
|
| Mass Screening | 2 | 2013 | 698 | 0.080 |
Why?
|
| Automation | 1 | 2010 | 55 | 0.080 |
Why?
|
| Primary Cell Culture | 2 | 2020 | 80 | 0.080 |
Why?
|
| Pseudophakia | 1 | 2009 | 5 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 203 | 0.080 |
Why?
|
| RNA Helicases | 1 | 2010 | 98 | 0.070 |
Why?
|
| Gene Ontology | 2 | 2021 | 38 | 0.070 |
Why?
|
| Cell Cycle Proteins | 3 | 2018 | 402 | 0.070 |
Why?
|
| Genetic Loci | 1 | 2009 | 116 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 497 | 0.070 |
Why?
|
| United States | 6 | 2023 | 8093 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2010 | 170 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2021 | 72 | 0.070 |
Why?
|
| Light | 1 | 2009 | 195 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1162 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2008 | 130 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2016 | 296 | 0.070 |
Why?
|
| DNA Helicases | 1 | 2010 | 198 | 0.070 |
Why?
|
| Multigene Family | 1 | 2008 | 106 | 0.070 |
Why?
|
| Family | 1 | 2010 | 245 | 0.070 |
Why?
|
| Protein Binding | 3 | 2018 | 1640 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 1290 | 0.070 |
Why?
|
| Optic Nerve | 2 | 2020 | 25 | 0.070 |
Why?
|
| DNA Primers | 2 | 2012 | 301 | 0.070 |
Why?
|
| Retina | 2 | 2023 | 132 | 0.060 |
Why?
|
| Europe | 3 | 2012 | 199 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2021 | 42 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1282 | 0.060 |
Why?
|
| Registries | 2 | 2025 | 924 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 981 | 0.060 |
Why?
|
| United Kingdom | 2 | 2020 | 85 | 0.060 |
Why?
|
| Protein Aggregation, Pathological | 2 | 2016 | 20 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 907 | 0.060 |
Why?
|
| Hypertension | 1 | 2011 | 612 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1192 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 415 | 0.060 |
Why?
|
| Sequestosome-1 Protein | 2 | 2015 | 9 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Internationality | 2 | 2018 | 46 | 0.060 |
Why?
|
| Riluzole | 1 | 2024 | 7 | 0.050 |
Why?
|
| Protein Folding | 2 | 2017 | 268 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2018 | 676 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 1565 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2018 | 962 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 992 | 0.050 |
Why?
|
| Gene-Environment Interaction | 1 | 2023 | 53 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 5 | 0.050 |
Why?
|
| Glucosylceramidase | 1 | 2022 | 7 | 0.050 |
Why?
|
| Base Composition | 1 | 2002 | 30 | 0.050 |
Why?
|
| Microtubules | 1 | 2023 | 210 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 154 | 0.050 |
Why?
|
| Electrons | 1 | 2002 | 33 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1586 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Homozygote | 1 | 2022 | 122 | 0.040 |
Why?
|
| Quality Control | 1 | 2022 | 79 | 0.040 |
Why?
|
| Epithelium | 1 | 2022 | 100 | 0.040 |
Why?
|
| Gene Library | 1 | 2002 | 102 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 1119 | 0.040 |
Why?
|
| Myoclonic Cerebellar Dyssynergia | 1 | 2021 | 1 | 0.040 |
Why?
|
| Rigor Mortis | 1 | 2021 | 1 | 0.040 |
Why?
|
| Glutamine | 1 | 2021 | 50 | 0.040 |
Why?
|
| Arabidopsis | 1 | 2002 | 83 | 0.040 |
Why?
|
| Muscle Hypotonia | 1 | 2021 | 7 | 0.040 |
Why?
|
| Genomics | 1 | 2024 | 384 | 0.040 |
Why?
|
| Zebrafish | 2 | 2019 | 374 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 3762 | 0.040 |
Why?
|
| Survival of Motor Neuron 2 Protein | 1 | 2021 | 6 | 0.040 |
Why?
|
| Lysosomes | 1 | 2022 | 173 | 0.040 |
Why?
|
| Microglia | 1 | 2024 | 250 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2011 | 5792 | 0.040 |
Why?
|
| Manometry | 1 | 2020 | 28 | 0.040 |
Why?
|
| Elasticity | 1 | 2020 | 45 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 198 | 0.040 |
Why?
|
| Rats | 2 | 2016 | 1994 | 0.040 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2019 | 7 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 119 | 0.040 |
Why?
|
| Acrylamides | 1 | 2019 | 13 | 0.040 |
Why?
|
| Thiazolidines | 1 | 2019 | 14 | 0.040 |
Why?
|
| Biomarkers | 1 | 2025 | 1480 | 0.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 23 | 0.040 |
Why?
|
| Coat Protein Complex I | 1 | 2019 | 5 | 0.040 |
Why?
|
| Arsenites | 1 | 2019 | 7 | 0.040 |
Why?
|
| Genome | 1 | 2002 | 285 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 2019 | 52 | 0.040 |
Why?
|
| Private Practice | 1 | 2019 | 8 | 0.040 |
Why?
|
| Dipeptides | 1 | 2019 | 68 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 339 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 257 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 139 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2019 | 201 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 158 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 178 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 181 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 407 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 111 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2019 | 138 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 897 | 0.030 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2018 | 3 | 0.030 |
Why?
|
| gamma-Crystallins | 1 | 2018 | 2 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2018 | 9 | 0.030 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2018 | 12 | 0.030 |
Why?
|
| Transfection | 1 | 2020 | 700 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 369 | 0.030 |
Why?
|
| Cholinergic Neurons | 1 | 2018 | 10 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2020 | 435 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2018 | 98 | 0.030 |
Why?
|
| Wings, Animal | 1 | 2018 | 28 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2018 | 32 | 0.030 |
Why?
|
| Genome, Human | 2 | 2010 | 237 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 754 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 62 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 269 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 456 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 283 | 0.030 |
Why?
|
| Armadillo Domain Proteins | 1 | 2018 | 27 | 0.030 |
Why?
|
| Gene Editing | 1 | 2022 | 328 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 171 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 24 | 0.030 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 35 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2018 | 105 | 0.030 |
Why?
|
| Epigenomics | 1 | 2017 | 62 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 325 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2018 | 117 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 422 | 0.030 |
Why?
|
| Decapodiformes | 1 | 2017 | 13 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2017 | 69 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 587 | 0.030 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2017 | 38 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 90 | 0.030 |
Why?
|
| Paralysis | 1 | 2016 | 17 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 238 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 844 | 0.030 |
Why?
|
| New Zealand | 1 | 2016 | 44 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2016 | 30 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 2016 | 68 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Clobetasol | 1 | 2016 | 6 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2016 | 141 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 2016 | 14 | 0.030 |
Why?
|
| Family Health | 1 | 2016 | 68 | 0.030 |
Why?
|
| Pruritus | 1 | 2016 | 32 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 405 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 964 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1784 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 160 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 235 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 355 | 0.030 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 13 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1269 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 15 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Genes | 1 | 2015 | 90 | 0.030 |
Why?
|
| TRPM Cation Channels | 1 | 2015 | 15 | 0.030 |
Why?
|
| Ubiquitins | 1 | 2015 | 41 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 367 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2016 | 234 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2015 | 62 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2014 | 97 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 896 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 591 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 856 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 740 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 202 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 374 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2016 | 189 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 419 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 542 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2013 | 26 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 559 | 0.020 |
Why?
|
| Germany | 1 | 2012 | 54 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 345 | 0.020 |
Why?
|
| Sweden | 1 | 2012 | 65 | 0.020 |
Why?
|
| Xanthomatosis, Cerebrotendinous | 1 | 2012 | 2 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 213 | 0.020 |
Why?
|
| HapMap Project | 1 | 2012 | 5 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2012 | 85 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2012 | 59 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1098 | 0.020 |
Why?
|
| Filamins | 1 | 2011 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Italy | 1 | 2011 | 69 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 1332 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2009 | 17 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2009 | 51 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 261 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2009 | 173 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 169 | 0.020 |
Why?
|